Lord, Abbett & Co
ELVN icon

Lord, Abbett & Co’s Enliven Therapeutics ELVN Stock Holding History

Lord, Abbett & Co’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-197,279
Closed -$3.88M – 534
2025
Q1 		$3.88M Sell
197,279
-188,932
-49% -$4.07M 0.01% 479
2024
Q4 		$8.69M Buy
386,211
+65,156
+20% +$1.69M 0.03% 401
2024
Q3 		$8.2M Buy
+321,055
New +$7.44M 0.03% 419

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lord, Abbett & Co's ELVN Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 197,279 shares — an estimated $3.88M sold.

Lord, Abbett & Co first reported a position in ELVN in Q3 2024 and held it in 3 quarters. The position peaked at $8.69M in Q4 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 197,279 Enliven Therapeutics shares in Q2 2025, an estimated $3.88M.
  • Lord, Abbett & Co first reported a position in Enliven Therapeutics in Q3 2024 and held it in 3 quarters.
  • Lord, Abbett & Co's Enliven Therapeutics position peaked at $8.69M in Q4 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.